MOTS-c vs NAD+: two different mitochondrial-research tools

MOTS-c vs NAD+. Both sit in the longevity / mitochondrial research strand and are often researched together, but one is a peptide and the other a cofactor. This guide is a research-reference comparison for Australian researchers. It makes no anti-ageing, longevity-outcome, or human-use claim.

A peptide versus a cofactor

MOTS-c is a 16-residue mitochondrial-derived peptide encoded within the mitochondrial genome, studied around AMPK signalling. NAD+ is a cellular cofactor — a dinucleotide, not a peptide — studied around sirtuin-pathway research. That is the core distinction: a genome-encoded peptide versus a metabolic cofactor, interrogating mitochondrial biology by different routes.

What the research reports for each

MOTS-c was identified and characterised by Lee and colleagues (Cell Metabolism, 2015), with its exercise-responsive, nucleus-translocating behaviour reported by Reynolds and colleagues (Nature Communications, 2021). NAD+’s role in sirtuin and PARP activity and age-related decline is surveyed by Verdin (Science, 2015) and reviewed by Rajman and colleagues (Cell Metabolism, 2018). The MOTS-c and NAD+ guides cover each in depth.

Where they sit together

Both sit in the longevity category, frequently referenced alongside each other and SS-31 as complementary mitochondrial-research tools. Researchers compare them to contrast the mitochondrial-derived-peptide class with cofactor-availability research — two different angles on the same broad research question.

Verification and compliance

Every batch is independently HPLC-tested by Janoshik before listing, with the certificate published in the lab-reports library. Neither is TGA-approved and neither is a therapeutic good; both are supplied strictly for in-vitro and laboratory research use only, with no anti-ageing, longevity-outcome, or human-use claim. This comparison is a research-reference summary, not a recommendation for any use.